Detail akcie NIAGEN BIOSCIENCE, INC online

Business Summary: Niagen Bioscience, Inc. specializes in nicotinamide adenine dinucleotide (NAD+) science and healthy-aging research. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Niagen Bioscience Inc revenues increased 36% to $95.6M. Net income increased from $1.4M to $13.3M. Revenues reflect Consumer Products Segments increase of 91% to $70.2M, Ingredients Segments increase from $10M to $23M, Analytical Reference Standards and Service segment increase of 51% to $2.4M. Net income benefited from Consumer Products Segments income increase from $7.7M to $18.7M.